Cargando…

The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment

BACKGROUND: Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a deeper understanding of treatment impact beyond clinical endpoints. Developing and administering PROMs for rare diseases poses un...

Descripción completa

Detalles Bibliográficos
Autores principales: Whittal, Amanda, Meregaglia, Michela, Nicod, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357707/
https://www.ncbi.nlm.nih.gov/pubmed/33462774
http://dx.doi.org/10.1007/s40271-020-00493-w
_version_ 1783737186963685376
author Whittal, Amanda
Meregaglia, Michela
Nicod, Elena
author_facet Whittal, Amanda
Meregaglia, Michela
Nicod, Elena
author_sort Whittal, Amanda
collection PubMed
description BACKGROUND: Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a deeper understanding of treatment impact beyond clinical endpoints. Developing and administering PROMs for rare diseases poses unique challenges because of small patient populations, disease heterogeneity, lack of natural history knowledge, and short-term studies. OBJECTIVE: This research aims to identify key factors to consider when using different types of PROMs in HTA for rare disease treatments (RDTs). METHODS: A scoping review of scientific and grey literature was conducted, with no date or publication type restrictions. Information on the advantages of and the challenges and potential solutions when using different types of PROMs for RDTs, including psychometric properties, was extracted and synthesized. RESULTS: Of 79 records from PubMed, 32 were included, plus 12 records from the grey literature. PROMs for rare diseases face potential data collection and psychometric challenges resulting from small patient populations and disease heterogeneity. Generic PROMs are comparable across diseases but not sensitive to disease specificities. Disease-specific instruments are sensitive but do not exist for many rare diseases and rarely provide the utility values required by some HTA bodies. Creating new PROMs is time and resource intensive. Potential solutions include pooling data (multi-site/international data collection), using computer-assisted technology, or using generic and disease-specific PROMs in a complementary way. CONCLUSIONS: PROMs are relevant in HTA for RDTs but pose a number of difficulties. A deeper understanding of the potential advantages of and the challenges and potential solutions for each can help manage these difficulties. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40271-020-00493-w.
format Online
Article
Text
id pubmed-8357707
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-83577072021-08-30 The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment Whittal, Amanda Meregaglia, Michela Nicod, Elena Patient Review Article BACKGROUND: Patient-reported outcome measures (PROMs) are used in health technology assessment (HTA) to measure patient experiences with disease and treatment, allowing a deeper understanding of treatment impact beyond clinical endpoints. Developing and administering PROMs for rare diseases poses unique challenges because of small patient populations, disease heterogeneity, lack of natural history knowledge, and short-term studies. OBJECTIVE: This research aims to identify key factors to consider when using different types of PROMs in HTA for rare disease treatments (RDTs). METHODS: A scoping review of scientific and grey literature was conducted, with no date or publication type restrictions. Information on the advantages of and the challenges and potential solutions when using different types of PROMs for RDTs, including psychometric properties, was extracted and synthesized. RESULTS: Of 79 records from PubMed, 32 were included, plus 12 records from the grey literature. PROMs for rare diseases face potential data collection and psychometric challenges resulting from small patient populations and disease heterogeneity. Generic PROMs are comparable across diseases but not sensitive to disease specificities. Disease-specific instruments are sensitive but do not exist for many rare diseases and rarely provide the utility values required by some HTA bodies. Creating new PROMs is time and resource intensive. Potential solutions include pooling data (multi-site/international data collection), using computer-assisted technology, or using generic and disease-specific PROMs in a complementary way. CONCLUSIONS: PROMs are relevant in HTA for RDTs but pose a number of difficulties. A deeper understanding of the potential advantages of and the challenges and potential solutions for each can help manage these difficulties. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40271-020-00493-w. Springer International Publishing 2021-01-19 2021 /pmc/articles/PMC8357707/ /pubmed/33462774 http://dx.doi.org/10.1007/s40271-020-00493-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review Article
Whittal, Amanda
Meregaglia, Michela
Nicod, Elena
The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment
title The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment
title_full The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment
title_fullStr The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment
title_full_unstemmed The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment
title_short The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment
title_sort use of patient-reported outcome measures in rare diseases and implications for health technology assessment
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357707/
https://www.ncbi.nlm.nih.gov/pubmed/33462774
http://dx.doi.org/10.1007/s40271-020-00493-w
work_keys_str_mv AT whittalamanda theuseofpatientreportedoutcomemeasuresinrarediseasesandimplicationsforhealthtechnologyassessment
AT meregagliamichela theuseofpatientreportedoutcomemeasuresinrarediseasesandimplicationsforhealthtechnologyassessment
AT nicodelena theuseofpatientreportedoutcomemeasuresinrarediseasesandimplicationsforhealthtechnologyassessment
AT whittalamanda useofpatientreportedoutcomemeasuresinrarediseasesandimplicationsforhealthtechnologyassessment
AT meregagliamichela useofpatientreportedoutcomemeasuresinrarediseasesandimplicationsforhealthtechnologyassessment
AT nicodelena useofpatientreportedoutcomemeasuresinrarediseasesandimplicationsforhealthtechnologyassessment